Evaluation of the long-term safety and tolerability of oral atogepant 60 mg once daily for preventive treatment of migraine: a phase 3, 40-week, multi-center extension to the advance trial

被引：0
|
作者：
Klein, B. [1 ]
Miceli, R. [2 ]
Severt, L. [2 ]
McAllister, P. [3 ]
Mechtler, L. [4 ]
McVige, J. [4 ]
Diamond, M. [5 ]
Marmura, M. J. [6 ]
Guo, H. [2 ]
Finnegan, M. [2 ]
Trugman, J. M. [2 ]
机构：
[1] Abington Neurol Associates Ltd, Abington, PA USA
[2] AbbVie, Madison, NJ USA
[3] New England Inst Neurol & Headache, Stamford, CT USA
[4] DENT Neurol Inst, Amherst, NY USA
[5] Diamond Headache Clin Ltd, Chicago, IL USA
[6] Thomas Jefferson Univ, Dept Neurol, Philadelphia, PA 19107 USA
来源：
CEPHALALGIA | 2021年 / 41卷 / 1_SUPPL期
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
AL077
引用
收藏
页码：235 / 235
页数：1
相关论文
共 34 条
  • [1] Evaluation of the long-term safety and tolerability of oral atogepant 60 mg once daily for preventive treatment of migraine: a phase 3, 40-week, multicenter extension to the advance trial
    Klein, B.
    Miceli, R.
    Severt, L.
    McAllister, P.
    Mechtler, L.
    McVige, J.
    Diamond, M.
    Marmura, M. J.
    Guo, H.
    Finnegan, M.
    Trugman, J. M.
    JOURNAL OF HEADACHE AND PAIN, 2021, 22 (SUPPL 2):
  • [2] Long-term safety and tolerability of atogepant for preventive treatment of migraine: a phase 3, 40-week, extension trial
    Klein, B.
    Miceli, R.
    Severt, L.
    McAllister, P.
    Mechtler, L.
    McVige, J.
    Diamond, M.
    Marmura, M.
    Guo, H.
    Finnegan, M.
    Trugman, J.
    EUROPEAN JOURNAL OF NEUROLOGY, 2022, 29 : 409 - 410
  • [3] Safety and tolerability results of atogepant for the preventive treatment of episodic migraine from a 40-week, open-label multicenter extension of the phase 3 ADVANCE trial
    Klein, Brad C.
    Miceli, Rosa
    Severt, Lawrence
    McAllister, Peter
    Mechtler, Laszlo
    McVige, Jennifer
    Diamond, Merle
    Marmura, Michael J.
    Guo, Hua
    Finnegan, Michelle
    Trugman, Joel M.
    CEPHALALGIA, 2023, 43 (01)
  • [4] Long-term Safety and Tolerability of Atogepant 60 mg Following Once Daily Dosing Over 1 Year for the Preventive Treatment of Migraine
    Ashina, Messoud
    Tepper, Stewart
    Reuter, Uwe
    Blumenfeld, Andrew
    Hutchinson, Susan
    Xia, Jing
    Miceli, Rosa
    Severt, Lawrence
    Finnegan, Michelle
    Trugman, Joel
    NEUROLOGY, 2021, 96 (15)
  • [5] Long-term Safety and Tolerability of Atogepant 60 mg Following Once Daily Dosing Over 1 Year for the Preventive Treatment of Migraine
    Ashina, M.
    Tepper, S. J.
    Reuter, U.
    Blumenfeld, A. M.
    Hutchinson, S.
    Xia, J.
    Miceli, R.
    Severt, L.
    Finnegan, M.
    Trugman, J. M.
    JOURNAL OF HEADACHE AND PAIN, 2021, 22 (SUPPL 1): : 46 - 46
  • [6] Long-term Safety and Tolerability of Atogepant 60mg Following Once Daily Dosing Over 1 Year for the Preventive Treatment of Migraine
    Ashina, M.
    Tepper, S. J.
    Reuter, U.
    Blumenfeld, A. M.
    Hutchinson, S.
    Xia, J.
    Miceli, R.
    Severt, L.
    Finnegan, M.
    Trugman, J. M.
    CEPHALALGIA, 2021, 41 (1_SUPPL) : 70 - 70
  • [7] Long-term Safety and Tolerability of Atogepant: Once Daily Dosing Over one Year for the Preventive Treatment of Migraine
    Ashina, M.
    Tepper, S.
    Reuter, U.
    Blumenfeld, A.
    Hutchinson, S.
    Xia, J.
    Miceli, R.
    Severt, L.
    Finnegan, M.
    Trugman, J.
    EUROPEAN JOURNAL OF NEUROLOGY, 2021, 28 : 152 - 152
  • [8] Long-term safety and tolerability of atogepant following once daily dosing over 1 year for the preventive treatment of migraine
    Ashina, M.
    Tepper, S. J.
    Reuter, U.
    Blumenfeld, A. M.
    Hutchinson, S.
    Xia, J.
    Miceli, R.
    Severt, L.
    Finnegan, M.
    Trugman, J. M.
    HEADACHE, 2021, 61 : 95 - 96
  • [9] Long-Term Safety, Tolerability, and Efficacy of Atogepant for the Preventive Treatment of Migraine: Interim Analysis of a Phase 3, Multicenter, Open-Label, 156-Week Long-Term Safety Extension Study
    Ashina, Sait
    Ashina, Messoud
    Holle-Lee, Dagny
    Tassorelli, Cristina
    Cho, Soo-Jin
    He, Molly Yizeng
    Ferreira, Rosa De Abreu
    Smith, Jonathan H.
    Pfleeger, Kimberly
    Trugman, Joel
    NEUROLOGY, 2024, 102 (12) : S7 - S8
  • [10] Once-daily oral atogepant for the long-term preventive treatment of migraine: Findings from a multicenter, randomized, open-label, phase 3 trial
    Ashina, Messoud
    Tepper, Stewart J.
    Reuter, Uwe
    Blumenfeld, Andrew M.
    Hutchinson, Susan
    Xia, Jing
    Miceli, Rosa
    Severt, Lawrence
    Finnegan, Michelle
    Trugman, Joel M.
    HEADACHE, 2023, 63 (01): : 79 - 88
1234